利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

113 条记录 (耗时 0.027 秒)

    Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
    1.
    发明授权
    Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen 失效
    使用lys-plasminogen预防和治疗由此导致的缺血事件和再灌注损伤

    公开(公告)号：US5520912A

    公开(公告)日：1996-05-28

    申请号：US257626

    申请日：1994-06-08

    申请人： Johann Eibl ,  Ludwig Pichler ,  Hans-Peter Schwarz

    发明人： Johann Eibl ,  Ludwig Pichler ,  Hans-Peter Schwarz

    IPC分类号： A61K38/00 ,  A61K38/43 ,  A61K38/46 ,  A61K38/48 ,  A61P9/00 ,  A61P9/10 ,  A01N37/18

    CPC分类号： A61K38/484 ,  Y10S514/802

    摘要： A treatment of ischemia and the attendant reperfusion injury entails the administration plasmin and plasmin-forming proteins, including lys-plasminogen and similar substances. Lys-plasminogen, which can be obtained from the proteolytic cleavage of glu-plasminogen, has been found to have a protective effect on tissue that has been injured by ischemic conditions. The administration of lys-plasminogen can used to treat subjects during the time of reperfusion and after reperfusion has already occurred. Lys-plasminogen also can be administered in conjunction with clot lysis therapies, such as those that employ tissue plasminogen activator and the like.

    摘要翻译： 缺血和伴随的再灌注损伤的治疗需要施用纤溶酶和纤溶酶形成蛋白，包括溶酶原纤溶酶原和类似物质。 已经发现，可以从葡萄糖分解纤维蛋白溶酶原的蛋白水解切割中获得的Lys-plasminogen对缺血条件损伤的组织具有保护作用。 溶血纤溶酶原的施用可以在再灌注期间和再灌注已经发生后用于治疗受试者。 Lys-纤溶酶原也可以与凝块溶解疗法结合使用，例如使用组织纤溶酶原激活剂等的那些。

    Treatment with lys-plasminogen of reperfusion injury and brain edema caused by ischemia
    2.
    发明授权
    Treatment with lys-plasminogen of reperfusion injury and brain edema caused by ischemia 失效
    用裂解纤溶酶原的再灌注损伤治疗和脑缺血引起的脑水肿

    公开(公告)号：US5597800A

    公开(公告)日：1997-01-28

    申请号：US345468

    申请日：1994-11-21

    申请人： Johann Eibl ,  Ludwig Pichler ,  Hans-Peter Schwarz

    发明人： Johann Eibl ,  Ludwig Pichler ,  Hans-Peter Schwarz

    IPC分类号： A61K38/00 ,  A61K38/43 ,  A61K38/46 ,  A61K38/48 ,  A61P9/00 ,  A61P9/10

    CPC分类号： A61K38/484 ,  Y10S514/802

    摘要： A treatment of ischemia and the attendant reperfusion injury entails the administration plasmin and plasmin-forming proteins, including lys-plasminogen and similar substances. Lys-plasminogen, which can be obtained from the proteolytic cleavage of glu-plasminogen, has been found to have a protective effect on tissue that has been injured by ischemic conditions. The administration of lys-plasminogen alone, in a dosage of about 10-1000 caseinolytic units/kg, can be used to treat subjects during the time of reperfusion and after reperfusion has already occurred. Lys-plasminogen also can be administered in conjunction with clot lysis therapies, such as those that employ tissue plasminogen activator and the like. Lys-plasminogen can also lessen cerebral edema which results from cerebral ischemia.

    摘要翻译： 缺血和伴随的再灌注损伤的治疗需要施用纤溶酶和纤溶酶形成蛋白，包括溶酶原纤溶酶原和类似物质。 已经发现，可以从葡萄糖分解纤维蛋白溶酶原的蛋白水解切割中获得的Lys-plasminogen对缺血条件损伤的组织具有保护作用。 在再灌注期间和再灌注已经发生后，以约10-1000个酪蛋白分解单位/ kg的剂量单独施用lys-plasminogen可用于治疗受试者。 Lys-纤溶酶原也可以与凝块溶解疗法结合使用，例如使用组织纤溶酶原激活剂等的那些。 Lys-纤溶酶原也可以减轻由脑缺血引起的脑水肿。